- Home
- NMG vs SGHT Comparison
NMG vs SGHT Comparison
Compare NMG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- SGHT
- Stock Information
- Founded
- NMG 2011
- SGHT 2011
- Country
- NMG Canada
- SGHT United States
- Employees
- NMG N/A
- SGHT N/A
- Industry
- NMG Other Metals and Minerals
- SGHT Medical Specialities
- Sector
- NMG Basic Materials
- SGHT Health Care
- Exchange
- NMG Nasdaq
- SGHT Nasdaq
- Market Cap
- NMG 251.2M
- SGHT 222.3M
- IPO Year
- NMG 2017
- SGHT 2021
- Fundamental
- Price
- NMG $1.65
- SGHT $3.48
- Analyst Decision
- NMG Strong Buy
- SGHT Buy
- Analyst Count
- NMG 2
- SGHT 8
- Target Price
- NMG $2.58
- SGHT $4.01
- AVG Volume (30 Days)
- NMG 37.8K
- SGHT 164.4K
- Earning Date
- NMG 08-13-2025
- SGHT 07-31-2025
- Dividend Yield
- NMG N/A
- SGHT N/A
- EPS Growth
- NMG N/A
- SGHT N/A
- EPS
- NMG N/A
- SGHT N/A
- Revenue
- NMG N/A
- SGHT $78,109,000.00
- Revenue This Year
- NMG N/A
- SGHT N/A
- Revenue Next Year
- NMG N/A
- SGHT $11.60
- P/E Ratio
- NMG N/A
- SGHT N/A
- Revenue Growth
- NMG N/A
- SGHT N/A
- 52 Week Low
- NMG $1.22
- SGHT $2.03
- 52 Week High
- NMG $2.58
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- NMG 42.81
- SGHT 37.53
- Support Level
- NMG $1.60
- SGHT $4.00
- Resistance Level
- NMG $1.67
- SGHT $4.33
- Average True Range (ATR)
- NMG 0.05
- SGHT 0.27
- MACD
- NMG -0.00
- SGHT -0.09
- Stochastic Oscillator
- NMG 27.83
- SGHT 6.21
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.